Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhuanggu Guanjie Capsule (ZGC) is a traditional Chinese medicine (TCM) herbal formula developed by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. for the treatment of osteoarthritis and osteoporosis. It has been used in China for nearly 30 years and is documented in the Chinese Pharmacopoeia (2020). The formulation consists of 12 herbal ingredients, including Rehmanniae Radix, Psoraleae Fructus, and Cibotium barometz. ZGC exerts its therapeutic effects primarily by modulating the NF-κB signaling pathway, which leads to a reduction in the production of inflammatory cytokines and proteins associated with joint degradation. Key bioactive constituents identified in the formula include psoralen, isopsoralen, and aspersaponin VI.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhuanggu Guanjie Capsule.